dupixent and semaglutide Side Effects, Risks FDA Safety Information New Eczema Drug Dupixent Approved

Rybelsus patients have now reported an increase in diagnosis of serious eye injuries such as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

This gradual elimination is why the medication maintains consistent blood levels throughout the week without daily dosing

Saroglitazar, a PPAR-/ agonist, at a dosage of 4 mg qd significantly improved ALT, liver fat content (LFC), insulin resistance, and atherogenic dyslipidemia in patients with MASLD/MASH (NCT03061721)

Acknowledgements We would like to express our sincere gratitude to Professor Zhentao Zhang from the Department of Neurology at Renmin Hospital, Wuhan University, for his invaluable guidance and support throughout this research

Presented for research literature review only Markowska M et al